PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic relief. With most consumers1 making treatment decisions in the pharmacy, the pharmacist's recommendation plays a pivotal role in helping patients return to their normal routines and make the moment theirs again. Key Findings:・Fast Relief from the First Dose: Patients reported fast relief fro…READ FULL ARTICLE
